rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Replimune Group, Inc.

REPL · Nasdaq

Health CareBiotechnologyLeading

REPL stood above a rising 150-day average in 26 of the last 52 weekly readings, including each of the last 11 weeks. It is 20.0% above that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−14 points in four weeks); Health Care: 28% (−9 points in four weeks).

SEC filings

Statistics

Rotation
Leading
Weeks in an uptrend
11 in a row
Industry in uptrend
18% -14 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$3.6M
Officials’ trades on record
0
Institutions holding
189 (+17)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 26 of 52 weeks.

21 Apr – 20 Oct
18%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$2.0M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months17
Buyers · sellers0 · 7
WhoDidSharesTraded
Emily Luisa HillChief Financial Officersold9,256at $14.2817 Aug 2026filed 19 Aug 2026
Baker Bros. Advisors LpDirector, 10% ownerbought126,394at $12.0611 Aug 2026filed 11 Aug 2026
Baker Bros. Advisors LpDirector, 10% ownerbought2,609,946at $12.0611 Aug 2026filed 11 Aug 2026
Andrew SchwendenmanChief Accounting Officersold7,632at $12.9710 Aug 2026filed 12 Aug 2026
Konstantinos XynosChief Medical Officersold11,447at $12.9710 Aug 2026filed 12 Aug 2026
Emily Luisa HillChief Financial Officersold11,448at $12.9710 Aug 2026filed 12 Aug 2026
Sushil PatelChief Executive Officersold39,341at $12.9710 Aug 2026filed 12 Aug 2026
Christopher SarchiChief Commercial Officersold12,000at $9.241 Jun 2026filed 3 Jun 2026
Emily Luisa HillChief Financial Officersold7,812at $5.0818 May 2026filed 20 May 2026
Sushil PatelChief Executive Officersold37,324at $5.0818 May 2026filed 20 May 2026
Philip Astley-SparkeDirectorsold17,657at $5.0818 May 2026filed 20 May 2026
Christopher SarchiChief Commercial Officersold8,626at $5.0818 May 2026filed 20 May 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders189+17 on the quarter
New · exited69 · 51
Reported value$1.0B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BAKER BROS. ADVISORS LPunchanged · filed 14 Aug 202611,045,336$122.3M00.0%
BlackRock, Inc.added · filed 7 Aug 20268,958,535$99.2M+2,719,296+43.6%
RTW INVESTMENTS, LPadded · filed 14 Aug 20267,411,581$82.0M+54,665+0.7%
Ridgeback Capital Investments L.P.new · filed 14 Aug 20267,310,656$80.9M+7,310,656
GOLDMAN SACHS GROUP INCadded · filed 14 Aug 20264,541,018$50.3M+2,263,742+99.4%
STATE STREET CORPadded · filed 7 Aug 20264,440,144$49.2M+657,907+17.4%
MONTANOVA CAPITAL, LLCadded · filed 14 Aug 20264,389,836$48.6M+168,000+4.0%
Boxer Capital Management, LLCadded · filed 14 Aug 20263,983,000$44.1M+2,808,000+239.0%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20262,896,004$32.1M+136,884+5.0%
FCPM III SERVICES B.V.unchanged · filed 14 Aug 20262,808,368$31.1M00.0%
31 Mar 2023 – 30 Jun 2026
109148186Mar 23Dec 23Dec 24Sep 25Jun 26

News

Class Action Lawsuit Filed: Replimune Group, Inc. (REPL) - Join by ...pr-inside.com · 5 Oct 2026Class Action Lawsuit Filed Against Replimune Group, Inc. (REPL) – Recover ...pr-inside.com · 27 Sep 2026Securities Class Action Lawsuit Filed Against Replimune Group, Inc. ...pr-inside.com · 24 Sep 2026Levi & Korsinsky Notifies Replimune Group, Inc. (REPL) Investors - ...pr-inside.com · 23 Sep 2026Lost Money on Replimune Group, Inc. (REPL)? Urged to Join Class Action ...pr-inside.com · 17 Sep 2026Securities Fraud Class Action Filed Against Replimune Group, Inc. (REPL) ...pr-inside.com · 14 Sep 2026Lost Money on Replimune Group, Inc. (REPL)? Join Class Action Before ...pr-inside.com · 8 Sep 2026Class Action Lawsuit Filed: Replimune Group, Inc. (REPL) – Join by ...pr-inside.com · 6 Sep 2026

Everyone who traded it

Philip Astley-Sparke Company insiderDirector · last 20 Aug 20260 · 14
Emily Luisa Hill Company insiderChief Financial Officer · last 17 Aug 20260 · 6
BAKER BROS. ADVISORS LP Company insiderDirector, 10% owner · last 11 Aug 20260 · 0
Felix Baker Company insiderDirector, 10% owner · last 11 Aug 20260 · 0
Andrew Schwendenman Company insiderChief Accounting Officer · last 10 Aug 20260 · 4
Konstantinos Xynos Company insiderChief Medical Officer · last 10 Aug 20260 · 9
Sushil Patel Company insiderChief Executive Officer · last 10 Aug 20260 · 9
Christopher Sarchi Company insiderChief Commercial Officer · last 1 Jun 20260 · 8
Baker Bros. Advisors (Gp) Llc Company insiderDirector, 10% owner · last 1 Apr 20260 · 0
Christy J. Oliger Company insiderDirector · last 1 Apr 20260 · 0
Dieter Weinand Company insiderDirector · last 1 Apr 20260 · 0
Joseph P. Slattery Company insiderDirector · last 1 Apr 20261 · 1

Same industry

MRNA ModernaLeading+167%
IOVA Iovance BiotherapeuticsLeading+141%
ABCL AbCellera BiologicsLeading+57%
ENTX Entera BioLeading+52%
HALO Halozyme TherapeuticsLeading+48%
XERS Xeris Biopharma HoldingsLeading+47%
XNCR XencorLeading+41%
HELP Helus PharmaLeading+39%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2026 · to 31 Mar 2026-117%
Debt to equityFY 2026 · to 31 Mar 20260.50×
Interest coverFY 2026 · to 31 Mar 2026-47.07×
Share count trendFY 2026 · to 25 Jun 20261.5%
Cash and equivalentsFY 2026 · to 31 Mar 2026$209.0M
Free cash flowFY 2026 · to 31 Mar 2026−$284.6M

Analyst forecasts

No analyst forecasts yet.